Drawing for QEGRITY

USPTO serial 79214319

QEGRITY

Reviewed by CopyMark Law Group

Reg. 5377480Status 709
Filing date
Status date
Registration date
Jan 16, 2018
Examiner
MILLER, JUSTIN T
Law office
TMO LAW OFFICE 114

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with QEGRITY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Christopher Bolinger

Christopher Bolinger Astellas Pharma Inc.2375 Waterview DriveTrademarks DepartmentNorthbrook, IL 60602

Goods and services

ClassDescriptionStatusFirst use
005Vaccines for human useSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 26, 2025INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Jul 3, 2025INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Jul 3, 2025INPCINVALIDATION PROCESSED—
Apr 14, 2025EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Apr 14, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 14, 2025ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Apr 14, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 14, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 2, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 2, 2024C71TCANCELLED SECTION 71—
Jan 16, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jun 25, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 3, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jun 3, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 3, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jun 3, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 3, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 3, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 2, 2018GPNXNOTIFICATION PROCESSED BY IB—
Feb 15, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
Feb 15, 2018FIMPFINAL DISPOSITION PROCESSED—
Feb 15, 2018GPARGRANT OF PROTECTION CREATED, TO BE SENT TO IB—
Jan 16, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 13, 2017ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Oct 10, 2017ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Oct 3, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 13, 2017NPUBNOTICE OF PUBLICATION—
Aug 22, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 21, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 18, 2017DOCKASSIGNED TO EXAMINER—
Aug 18, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 17, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance